Previous 10 | Next 10 |
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in pati...
(Source: Evil Speculator) Anyone thinking 2018 investing hasn’t been anything other than a proverbial roller-coaster ride needs their sanity checked. Thankfully, the end of the year is fast approaching, and if given the option to choose - bull or bear - I would have, and did, opt for ...
Adaptimmune Therapeutics PLC (ADAP) Q3 2018 Earnings Conference Call November 6, 2018 08:00 AM ET Executives Juli Miller - Director of IR James Noble - CEO & Director Rafael Amado - Chief Medical Officer Adrian Rawcliffe - Chief Financial Officer Analysts Jonathan Cha...
Adaptimmune (NASDAQ: ADAP ): Q3 GAAP EPS of $0.01 beats by $0.05 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with anticipated dose escalation to Cohort 2 early 2019 ~$26 mill...
PHILADELPHIA and OXFORD, United Kingdom, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S. markets open on...
Gainers: ESEA +173% . JTPY +142% . TOPS +108% . NETE +64% . GLBS +54% . ARII +51% . DCIX +50% . PXS +40% . SINO +35% . NVMM +32% . More news on: Euroseas Ltd., JetPay Corporation, TOP Ships Inc., Stocks on the move, , Top stock market news, Read mo...
ADAP -34% on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more ...
Adaptimmune Therapeutics plc (NASDAQ: ADAP ) slumps 37% premarket on light volume on the heels of its announcement of initial data from the first two cohorts of its ongoing studies evaluating its MAGE-A10 and MAGE-A4 SPEAR T-cells. The results were presented at ESMO in Munich. ...
PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MA...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...